New potential antimalarial agents: Therapeutic-index evaluation of pyrroloquinazolinediamine and its prodrugs in a rat model of severe malaria

Antimicrobial Agents and Chemotherapy

Volumn 50, Issue 5, 2006, Pages 1649-1655

  Xie, Lisa H ^a   Li, Qigui ^a   Lin, Ai J ^a   Smith, Kirsten ^a   Zhang, Jing ^a   Skillman, Donald S ^a  

^a WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT; ARTESUNATE; BISETHYLCARBAMYLPYRROLOQUINAZOLINEDIAMINE; PRODRUG; PYRROLE DERIVATIVE; PYRROLOQUINAZOLINEDIAMINE; PYRROLOQUINAZOLINEDIAMINE DERIVATIVE; TETRAACETAMIDE PYRROLOQUINAZOLINEDIAMINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DRUG POTENCY; DRUG SAFETY; MALARIA; MAXIMUM TOLERATED DOSE; MOUSE; NONHUMAN; PARASITEMIA; PLASMODIUM BERGHEI; PRIORITY JOURNAL; RAT; STANDARD;

ANIMALS; ANTIMALARIALS; ARTEMISININS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; MALARIA; MAXIMUM TOLERATED DOSE; PARASITEMIA; PLASMODIUM BERGHEI; PRODRUGS; PYRROLES; QUINAZOLINES; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; SESQUITERPENES; THERAPEUTIC EQUIVALENCY;

EID: 33646453477     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.50.5.1649-1655.2006     Document Type: Article

References (32)

1. Andersen, S. L., A. Ager, P. McGreevy, B. G. Schuster, D. Wesche, R. Kuschner, C. Ohrt, W. Ellis, R. Rossan, and J. Berman. 1995. Activity of azithromycin as a blood schizonticide against rodent and human plasmodia in vivo. Am. J. Trop. Med. Hyg. 52:159-161.
2. Burghaus, P. A., B. T. Wellde, T. Hall, R. L. Richards, A. F. Egan, E. M. Riley, W. R. Ballou, and A. A. Holder. 1996. Immunization of Aotus nancymai with recombinant C terminus of Plasmodium falciparum merozoite surface protein 1 in liposomes and alum adjuvant does not induce protection against a challenge infection. Infect. Immun. 64:3614-3619.
3. Carvalho, L. J., S. G. Oliveira, F. A. Alves, M. C. Brigido, J. A. Muniz, and C. T. Daniel-Ribeiro. 2000. Aotus infulatus monkey is susceptible to Plasmodium falciparum infection and may constitute an alternative experimental model for malaria. Mem. Inst. Oswaldo Cruz 95:363-365.
4. Collins, W. E., J. C. Skinner, J. R. Broderson, B. B. Richardson, N. S. Ma, and P. S. Stanfill. 1991. Infection of Aotus vociferans monkeys with different strains of Plasmodium falciparum. J. Parasitol. 77:562-567.
5. Dascombe, M. J., and J. Y. Sidara. 1997. Ketanserin effects on thermoregulation in malarial and normal rats. Ann. N.Y. Acad. Sci. 813:392-397.
6. Davoll, J., A. M. Johnson, H. J. Davies, O. D. Bird, J. Clarke, and E. F. Elslager. 1972. Folate antagonists. 2. 2,4-Diamino-6-((aralkyl and (heterocyclic)methyl)amino)quinazolines, a novel class of antimetabolites of interest in drug-resistant malaria and Chagas' disease. J. Med. Chem. 15:812-826.
7. Deglin, S. M., J. M. Deglin, and E. K. Chung. 1977. Drug-induced cardiovascular diseases. Drugs 14:29-40.
8. Dominguez, J. N., J. E. Charris, G. Lobo, N. G. de Dominguez, M. M. Moreno, F. Rigginoe, E. Sanchez, J. Olson, and P. J. Rosenthal. 2001. Synthesis of quinolinyl chalcones and evaluation of their antimalarial activity. Eur. J. Med. Chem. 36:555-560.
9. Dow, G. S., J. A. Reynoldson, and R. C. A. Thompson, 1999. Plasmodium berghei: a new rat model for assessment of blood schizonticidal activity. Exp. Parasitol. 93:92-94.
10. Dow, G. S., T. H. Hudson, M. Vahey, and M. L. Koenig. 2003. The acute neurotoxicity of mefloquine may be mediated through a disruption of calcium homeostasis and ER function in vitro. Malaria J. 2:14-19.
11. Dow, G. S., M. L. Koenig, L. Wolf, L. Gerena, M. Lopez-Sanchez, T. H. Hudson, and A. K. Bhattacharjee. 2004. The antimalarial potential of 4-quinolinecarbinolamines may be limited due to neurotoxicity and cross-resistance in mefloquine-resistant Plasmodium falciparum strains. Antimicrob. Agents Chemother. 48:2624-2632.
12. Elslager, E. F., O. D. Bird, J. Clarke, S. C. Perricone, and D. F. Worth. 1972. Folate antagonists. 9. 2,4-Diamino-6-((aralkyl)alkylamino)quinazolines, a potent class of antimetabolites with prodigious antimalarial effects. J. Med. Chem. 15:1138-1146.
13. Guan, J., Q. Zhang, M. O'Neil, N. Obaldia III, A. Ager, L. Gerena, and A. J. Lin. 2005. Antimalarial activity of new pyrrolo[3,2-f]Quinazoline-1,3- Diamine derivatives. Antimicrob. Agents Chemother. 49:4928-4933.
14. Han, H. K., and G. L. Amidon. 2000. Targeted prodrug design to optimize drug delivery. AAPS Pharm. Sci. 2:E6.
15. Holloway, P. A., S. Krishna, and N. J. White. 1991. Plasmodium berghei: lactic acidosis and hypoglycaemia in a rodent model of severe malaria; effects of glucose, quinine, and dichloroacetate. Exp. Parasitol. 72:123-133.
16. Hua, H., M. Cheng, X. Li, and Y. Pei. 2002. A new pyrroloquinazoline alkaloid from Linaria vulgaris. Chem. Pharm. Bull. (Tokyo) 50:1393-1394.
17. International Conference on Harmonisation. 1994. Harmonised tripartite guidance. Guidance for industry: detection of toxicity to reproduction for medicinal products. [Online.] http://www.fda.gov/cder/guidance/s5a.pdf.
18. Johns Hopkins Research Institute. 2004. Malaria. A grand challenge. Proceedings of a Johns Hopkins Research Institute Meeting. 25-26 March 2004, Baltimore, Maryland, USA. Int. J. Parasitol. 34:1413-1554.
19. Jones, T. R., D. F. Stroncek, A. S. Gozalo, N. Obaldia III, E. M. Andersen, C. Lucas, D. L. Narum, A. J. Magill, B. K. Sim, and S. L. Hoffman. 2002. Anemia in parasite- and recombinant protein-immunized Aotus monkeys infected with Plasmodium falciparum. Am. J. Trop. Med. Hyg. 66:672-679.
20. Kim, S. Y., and N. L. Benowitz. 1990. Poisoning due to class IA antiarrhythmic drugs. Quinidine, procainamide and disopyramide. Drug Safety 5:393-420.
21. Ledig, K. W. 3 October 1978. 7-(Substituted)-7H-pyrrolo[3,2,-f] quinazoline-1,3-diamines. U.S. patent 4,118,561.
22. Lee, H. J., J. S. Cooperwood, Z. You, and D. H. Ko. 2002. Prodrug and antedrug: two diametrical approaches in designing safer drugs. Arch. Pharm. Res. 25:111-136.
23. Li, C., E. Seixas, and J. Langhorne. 2001. Rodent malaria: the mouse as a model for understanding immune responses and pathology induced by the erythrocytic stages of the parasite. Med. Microbiol. Immunol. 189:115-126.
24. Li, Q. G., Y. Z. Si, P. Lee, E. Wong, L. H. Xie, D. E. Kyle, and G. S. Dow. 2003. Efficacy comparison of intravenous artelinate and artesunate in Plasmodium berghei-infected Sprague-Dawley rats. Parasitology 126:283-291.
25. Li, Q. G., M. P. Kozar, L. H. Xie, T. Shearer, Y. Z. Si, L. Anova, J. Zhang, A. J. Lin, W. K. Milhous, and D. R. Skillman. 2004. Potential antimalarial agents, pyrroloquinazoline analogs, for blood or prophylactic stage malarias. Am. J. Trop. Med. Hyg. 71:90.
26. Medicines for Malaria Venture. 2005. Curing malaria together. [Online.] http: //www.mmv.org/pages/content_frame.asp?center_?page=page1_0004_1.htm.
27. 26a. National Research Council. 1996. Guide for the care and use of laboratory animals. National Research Council, Washington, D.C.
28. Neimark, H., A. Barnaud, P. Gounon, J. C. Michel, and H. Contamin. 2002. The putative Haemobartonella that influences Plasmodium falciparum parasitaemia in squirrel monkeys is a haemotrophic mycoplasma. Microbes Infect. 4:693-698.
29. Puri, S, K., and N. Singh. 2000. Azithromycin: antimalarial profile against blood- and sporozoite-induced infections in mice and monkeys. Exp. Parasitol. 94:8-14.
30. Pye, D., C. M. O'Brien, P. Franchina, C. Monger, and R. F. Anders. 1994. Plasmodium falciparum infection of splenectomized and intact Guyanan Saimiri monkeys. J. Parasitol. 80:558-562.
31. Scheller, L. F., K. C. Stump, and A. F. Azad. 1995. Plasmodium berghei: production and quantitation of hepatic stages derived from irradiated sporozoites in rats and mice. J. Parasitol. 81:58-62.
32. Xie, L. H., T. O. Johnson, P. J. Weina, Y. Z. Si, A. Haeberle, R. Upadhyay, E. Wang, and Q. G. Li. 2005. Risk assessment and therapeutic indices of artesunate and artelinate in P. berghei infected and uninfected rats. J. Int. Toxicol. 24:251-264.